Disease Landscape and Forecast Insights

In a landmark FDA ruling, Ocrevus became the first DMT approved for the treatment of PP-MS in March 2017. Although the drug’s efficacy appears more modest than in patients with relapsing forms of…

MARKET OUTLOOK The U.S. ulcerative colitis (UC) and Crohn’s disease (CD) markets include the predominantly entrenched TNF-α inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s…

Treatment of neuropathic pain involves the use of drugs from several drug classes, including antidepressants, antiepileptic drugs, local anesthetics, dual-acting opioid analgesics, and opioid…

Incyte/Novartis’s Jakafi/Jakavi (ruxolitinib) is the first and only drug approved for MF in the United States (2011) and EU5 (2012). While Jakafi/Jakavi offers a therapeutic option for patients…

The algorithms for treating psoriatic arthritis (PsA) are unique among rheumatic diseases because most PsA patients receive prior treatment by dermatologists for psoriasis, with many of the same…

Gram-negative infections (GNIs) account for a large portion of hospital-treated infections (HTIs), which represent a high-value segment of the antibacterial market given the severity of these…

Abstract: The mature rheumatoid arthritis (RA) market boasts ten different biologics representing several distinct drug classes, including blockbuster tumor necrosis factor alpha (TNF-α)…

Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used throughout the course of disease…

Antineoplastic treatment in stage IV renal cell carcinoma is with targeted agents. The market entry of an immune checkpoint inhibitor has revolutionized the treatment algorithm for previously…

Obesity is a growing epidemic in the United States. Despite the high prevalence, only a limited number of antiobesity drugs are available, and lifestyle interventions remain the cornerstone of…

In the past decade, tumor necrosis factor-alpha (TNF-α) inhibitors, AbbVie’s Humira and Amgen’s Enbrel, and Janssen’s interleukin (IL)-12/23 inhibitor Stelara have been leading the U.S…

AD is a chronic inflammatory skin disease marked by pruritus, eczema, and, in moderate to severe patients, frequent relapse. Standard AD treatments aim to protect the skin barrier through…